Tag: Severe eosinophilic asthma

Approved by the FDA in 2017, benralizumab is a biologic medication designed for the add-on maintenance treatment of severe eosinophilic asthma. This article explains **what class of drug is benralizumab** and its unique mechanism of targeting the interleukin-5 (IL-5) receptor to reduce eosinophil-driven inflammation.

First approved in 2015 for severe eosinophilic asthma, the biologic medication Nucala (mepolizumab) targets the protein interleukin-5 (IL-5) to reduce eosinophil levels, thereby managing a range of inflammatory conditions. It is not a quick-relief treatment but an add-on maintenance therapy.